Lyell Immunopharma, Inc.
-
Ticker
LYEL
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in South San Francisco, California
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and
…More self-renew to drive durable tumor cytotoxicity. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington.
REPORT RATINGS
5.0 / 5.0 (1)
Lyell Immunopharma, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Lyell Immunopharma, Inc.
Most Recent Responsibility Report
MOST RECENT
2023 ESG Report
Report Locked. Lyell Immunopharma, Inc. has reached its limit for free report views.
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Lyell Immunopharma, Inc. Sustainability Report, Lyell Immunopharma, Inc. Corporate Social Responsibility Report, Lyell Immunopharma, Inc. CSR Report, Lyell Immunopharma, Inc. Corporate Responsibility, Lyell Immunopharma, Inc. CR Report, Lyell Immunopharma, Inc. Citizenship Report, Lyell Immunopharma, Inc. ESG Report, and Lyell Immunopharma, Inc. Environmental Report online.